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Objective: To evaluate the clinical efﬁ  cacy of the early administration of zofenopril in a group of 
patients with and without metabolic syndrome (MS+ and MS–) and anterior myocardial infarction 
enrolled in the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study.
Methods: Patients were randomized double-blind to zofenopril (n = 719) or placebo (n = 699) 
for 6 weeks. The primary end point was the effect of treatment on the 6-week combined occur-
rence of death and severe congestive heart failure. The secondary end point was the 1-year 
mortality rate.
Results: Of the 1418 patients included in this post-hoc analysis, 686 (48.3%) had MS. After 
6 weeks of treatment zofenopril signiﬁ  cantly reduced the incidence of all-cause death and severe 
congestive failure (risk reduction: 69%, 95% CI: 7–78; 2p = 0.002) in MS+ patients. This was 
the case for 1-year mortality, too (29%, 95% CI: 4–41; 2p = 0.048). Zofenopril was effective 
also in MS− patients but the amount of relative risk reduction was less than in MS+ for both 
the primary (–11%; 2p = 0.61) and secondary endpoint (–19%; 2p = 0.025).
Conclusions: Results of this post-hoc analysis of the SMILE Study demonstrate the striking 
beneﬁ  t of early administration of zofenopril in MS+ patients with acute anterior myocardial 
infarction.
Keywords: SMILE Study, angiotensin converting enzyme inhibitor, zofenopril, myocardial 
infarction, metabolic syndrome
Introduction
Early treatment with angiotensin-converting enzyme (ACE) inhibitors of patients with 
acute myocardial infarction greatly improves their in-hospital and long-term survival 
(Borghi et al 1998; Donnelly and Manning 2007). Most of the beneﬁ  t of ACE inhibi-
tors in these patients is due to blockade of both plasma and tissue renin-angiotensin 
system, activated during the early phase of myocardial infarction (Omland et al 1993; 
Walsh et al 1999).
Metabolic syndrome (MS) is a constellation of cardiovascular risk factors, such as 
abdominal obesity, atherogenic dyslipidemia, hypertension, and insulin resistance or 
glucose intolerance (Eckel et al 2005), and it is associated with an increased cardiovas-
cular morbidity and mortality (Hu et al 2004; Hunt et al 2004). MS has a prevalence 
of 15%–20% in the general population (Ford et al 2002) but it occurs in nearly 50% 
of unselected patients with acute myocardial infarction (Zeller et al 2005). In these 
patients MS further enhances the risk of death from all causes as well as the risk of 
cardiovascular complications (Ninomiya et al 2004; Levantesi et al 2005). Recent 
evidence supports the hypothesis that the hyperinsulinemia that characterizes the 
subjects with MS may be associated with an overexpression of vascular angiotensin Vascular Health and Risk Management 2008:4(3) 666
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II-AT1 receptors leading to an exaggerated activation of the 
tissue renin-angiotensin system, a condition particularly 
harmful in patients with acute myocardial infarction (Muller 
et al 2000; Zhang et al 2005). For this reason ACE inhibition 
may play a key role in patients with myocardial infarction 
and MS (Prasad and Quyyumi 2004).
Zofenopril calcium is a sulfhydryl ACE inhibitor 
(Borghi et al 2004) which has been shown in the SMILE 
(Survival of Myocardial Infarction Long-term Evaluation) 
Study to improve both short- and long-term outcome when 
administered within the ﬁ  rst 24 hours of an acute myocar-
dial infarction (Ambrosioni et al 1995). The present study 
is a post-hoc analysis of the SMILE Study to evaluate the 
effects of the early administration of zofenopril on the 
clinical outcome in a subgroup of patients with (MS+) and 
without MS (MS–).
Material and methods
Subjects
The SMILE Study included 1556 patients admitted to 154 
Italian coronary care units who were randomized to study 
treatment with an ACE inhibitor or placebo in addition to 
recommended pharmacological treatment. Details of the 
study protocol have been published elsewhere (Ambrosioni 
et al 1995). In the main SMILE Study, eligible patients were 
considered those of either gender, aged 18–80 years, present-
ing to the intensive care unit within 24 hours of the onset 
of chest pain typically associated with electrocardiographic 
signs of myocardial infarction of the anterior wall and not 
eligible for thrombolytic therapy because of late ad  mission 
to the intensive care unit or contraindications to systemic 
ﬁbrinolysis. Upon enrollment patients were randomly allo-
cated according to ﬁxed blocks to receive oral zofenopril 
or placebo.
Patients were excluded from the study if they had 
on admission: a) cardiogenic shock (Killip class 4), b) 
systolic blood pressure below 100 mmHg (measured with 
the patient supine), c) serum creatinine concentra  tion 
above 2.5 mg/dL (221 mmol/L), d) history of congestive 
heart failure, e) current treatment with an ACE inhibitor, 
f) contraindications to the use of ACE inhibitors, or g) 
were unable or unwilling to give informed consent. All 
potentially eligible patients received standard therapy 
including analgesic agents, beta-blockers, nitrates, calcium 
antagonists, aspirin, inotropic drugs, diuretic agents, and 
anticoagulants as indicated.
The initial dose of study medication was 7.5 mg and 
was repeated after 12 hours and progressively doubled 
up to the ﬁ  nal dose of 30 mg twice daily if systolic blood 
pressure remained above 100 mmHg and there were no 
signs or symp toms of hypotension. Patients were evaluated 
while they were in the hospital (between day 7 and day 
15 from index myocardial infarction) after 4 weeks, and 
at the end of the double-blind treatment period (6 weeks), 
during which time they could be treated with any other 
drug except ACE inhibitors. On completion of the 6-week 
double-blind period, the patients stopped taking the study 
medica  tions but continued treatment in an open-label 
fashion for additional 11 months (±1) when their vital 
status was blind  ly evaluated.
The study was conducted in accordance with the Declara-
tion of Helsinki and was approved by the institutional review 
board of the University of Bologna as well as by the local 
ethics committees when required. All patients provided writ-
ten informed consent prior to inclusion into the study. Full 
details on the SMILE protocol are reported in Ambrosioni 
et al (1995) and Borghi et al (2003).
In the present post-hoc analysis a subgroup of 1418 
MS+ and MS– patients were considered. Patients were 
classiﬁ  ed as having MS according to modiﬁ  ed NCEP-ATP 
III criteria (NCEP ATP III 2001; Grundy et al 2004), ie, 
concomitant presence of at least 3 over 5 among the fol-
lowing risk factors: a) treated hypertension or blood pres-
sure  130/85 mmHg, b) serum triglycerides  150 mg/dL, 
c) serum HDL cholesterol  40 mg/dL in men and  50 mg/dL 
in women, d) overweight (BMI  25 kg/m2), and e) fasting 
blood glucose  110 mg/dL.
Study end points
The primary study end point was the combined occurrence of 
death or severe congestive heart failure during the 6 weeks 
of treatment with zofenopril or placebo, both given in addi-
tion to conventional treatment. Death or presence of severe 
congestive heart failure was considered as a single event for 
each patient and their prevalence was calculated according 
to whichever occurred ﬁ  rst.
The causes of death were classiﬁ  ed by the principal inves-
tigators and reviewed by an end-point committee acting on 
the basis of a blinded review. All deaths occurring during the 
trial were classiﬁ  ed as due to cardiac or non-cardiac causes. 
Cardiac causes included pro  gressive heart failure, sudden 
death, recurrent myocardial infarction, and cardiac rupture. 
Non-cardiac causes included cerebrovascular events, pulmo-
nary embolism, and non-vascular causes. Progressive heart 
failure was classiﬁ  ed on the basis of pump failure and the 
oc  currence of cardiogenic shock. Sudden death was deﬁ  ned Vascular Health and Risk Management 2008:4(3) 667
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as sudden, unexpected death occurring within 1 hour after 
the onset of new symptoms.
Predeﬁ  ned secondary end point was the effect of 6-week 
double-blind treatment on cumulative 1-year mortality.
Statistical analysis
The present study is a post hoc analysis of the main SMILE 
Study data carried out on MS+ and MS– patients. The 
baseline characteristics and the distribution of the various 
parameters for the MS+ and MS– patients were compared 
using a Chi-square test for categorical variables (with Yates’ 
continuity correction where appropriate) and a standard 
normal t-test for continuous variables. A Chi-square test 
was also employed to compare the frequency of metabolic 
risk factors between the placebo and active treatment group. 
Relative risk reductions and corresponding 95% conﬁ  dence 
in  tervals (CI) were calculated for both the primary and 
secondary end point, separately for the MS+ and MS– 
patients. The Chi-square analysis was applied to data with 
the Mantel-Haenzsel extension for the comparisons between 
the two treatment groups. Time-to-event curves were drawn 
using Kaplan-Meier estimates. All analyses were performed 
on an intention-to-treat basis and all p values are two-tailed 
(Norman and Streiner 2000).
Results
Patients
Of the 1418 included in this post-hoc analysis, 686 (48.3%) 
were MS+ and 732 MS–. Placebo and zofenopril (Menarini 
Group, Florence, Italy) treatment was equally distributed 
within MS+ (n = 324 for placebo and n = 362 for zofenopril) 
and MS– patients (n = 375 and n = 357).
The MS+ and MS– groups were homogeneous for base-
line clinical characteristics, except for signiﬁ  cantly higher 
body weight and blood pressure values, and signiﬁ  cantly 
greater prevalence of diabetes and hypertension in the MS+ 
group (Table 1). A trend (p = 0.05) for a greater use of antihy-
pertensive drugs was observed in MS+ patients at enrolment 
(Table 1), but during the 6 weeks of double-blind therapy 
concomitant pharmacologic treatments were not different 
between the two treatment groups (data not shown).
As shown in Table 2, the prevalence of the different 
markers of the metabolic syndrome was similar in the two 
randomization groups. In particular hypertension and hyper-
glycemia were the most common risk factors and occurred 
in more than 50% of study population.
Primary outcome measures
During the 6 weeks of treatment, the rate of death or severe 
congestive heart failure was less in MS+ than in MS– patients. 
In MS+ patients a signiﬁ  cant relative risk reduction of a major 
cardiovascular event was observed with zofenopril compared 
with placebo (69%, 95% CI: 7%–78%; 2p = 0.002) (Figure 1, 
left panel). Cumulative incidence of combined death and 
severe heart failure in the course of the 6 weeks of treatment 
Table 1 Baseline characteristics of study population
 MS+   MS–   p
 (n  = 686) (n  = 732)
Age (years, means ± SD)  63 ± 10  65 ± 10  NS
Gender ratio   69/31  76/24  NS
(male/female, %)
Body weight   77 ± 11  70 ± 10   0.01
(kg, means ± SD)
Current smokers (%)  57  60  NS
Diabetes mellitus (%)  30  15   0.01
Previous myocardial   18  17  NS
infarction (%)
Hypertension (%)  46  34   0.01
Medication (%)     
 Antiplatelet  agents  56  61  NS
  Calcium channel blockers  16  13  NS
 β -blockers 44  39  NS
 Diuretics  11  9   0.05
 Nitrates  41  41  NS
Hours to randomization      
(% of patients)
   6 44  42  NS
 6–12  27  31  NS
   12 29  27  NS
Hours to randomization   2 ± 1  2 ± 1  NS
(means ± SD)
Hours to treatment   3 ± 1  3 ± 1  NS
(means ± SD)
Killip class on admission   13  12  NS
 1 (%)
Peak CK (U*10–3) 2  ± 1  1±1 NS
SBP (mmHg, means ± SD)  143 ± 19  132 ± 19   0.01
DBP (mmHg, means±SD) 88  ± 11  82 ± 11   0.01
HR (mmHg, means ± SD)  83 ± 15 81  ± 16  NS
Abbreviations: CK, creatinine kinase; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; HR, heart rate.
Table 2 Prevalence of the different markers of metabolic syndrome 
in the two randomization groups
 Placebo  Zofenopril 
 (n  = 699)  (n = 719)
Obesity (%)  32  32
Hypertriglyceridemia (%)  34  33
Low HDL cholesterol (%)  41  37
Hyperglycemia 60  62
Hypertension (%)  68  71Vascular Health and Risk Management 2008:4(3) 668
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in the MS+ group was signiﬁ  cantly (p = 0.017) greater under 
placebo than under zofenopril (Figure 1, right panel).
Secondary outcome measures
The 1-year mortality rates for the MS+ and MS− patients 
according to their original treatment assignments are shown 
in Figure 2. Patients who received zofenopril for 6 weeks 
were signiﬁ  cantly more likely to survive than patients given 
placebo. However, risk of death was lower and relative risk 
reduction greater in MS+ than in MS– (–29% vs –19%, 
relative risk reduction in MS+ vs MS–).
No dose-response effect between zofenopril and clinical 
events has been observed for either primary or secondary 
outcomes.
Blood pressure proﬁ  le
At the end of the 6-week treatment period supine systolic and 
diastolic blood pressure reduction was signiﬁ  cantly greater 
in MS+ than in MS– patients (Figure 3). As a consequence 
the ﬁ  nal blood pressure levels achieved after 6 weeks of 
treatment were 129 ± 7/81 ± 9 in MS+ and 128 ± 8/78 ± 10 
in MS– with no difference among the two populations of 
patients. The extent of blood pressure decrease was slightly 
enhanced in patients with MS and treated with zofenopril, 
and this difference achieved a formal statistical signiﬁ  cance 
for systolic blood pressure (p   0.05). Heart rate was com-
parably reduced in both groups (data not shown).
Discussion
This post-hoc analysis of the SMILE Study (Ambrosioni 
et al 1995) demonstrated that early treatment with zofeno-
pril of MS+ patients with non-thrombolyzed anterior acute 
myocardial infarction a) reduces the 6-week combined 
incidence of death and severe refractory congestive heart 
failure, and b) improves long-term survival after withdrawal 
of treatment. The relative risk reduction for the two study 
end points under zofenopril in MS+ patients was 69% and 
29%, while it was deﬁ  nitely lower in MS– patients (–11% 
and –19%, respectively).
To our knowledge this is the ﬁ  rst evidence from a ran-
domized, placebo-controlled study of the prognostic beneﬁ  t 
of early ACE inhibition in MS+ patients with acute myocar-
dial infarction. Indeed, there are some data in the literature 
proving that antagonism of the renin-angiotensin system 
with ACE inhibitors provides substantial long-term clini-
cal beneﬁ  ts in high risk patients. However, they are limited 
to patients with diabetes and acute myocardial infarction 
(Zuanetti et al 1997; Gustafsson et al 1999) or diabetes and
Figure 1 Combined occurrence of death and severe heart failure at 6 weeks (left panel) and cumulative incidence during the treatment period (right panel) in patients with 
(MS+) and without metabolic syndrome (MS−) treated with placebo or zofenopril.
0
2
4
6
8
10
12
14
0         1        2         3         4         5        6
Time (weeks)
E
v
e
n
t
 
r
a
t
e
 
(
%
)
0
2
4
6
8
10
12
14
Placebo
(n = 324)
Zofenopril
(n = 362)
Placebo
(n = 375)
Zofenopril
(n = 357)
E
v
e
n
t
 
r
a
t
e
 
(
%
) RRR –69%
(95% CI: 7–78)
2p = 0.002
MS+ MS–
RRR –11%
(95% CI: –4–27)
2p = 0.61
MS+ (2p = 0.017)
MS– (2p = 0.52)
Placebo
(n = 375)
Zofenopril
(n = 357)
Placebo
(n = 324)
Zofenopril
(n = 362)Vascular Health and Risk Management 2008:4(3) 669
Zofenopril in metabolic syndrome and myocardial infarction
chronic coronary syndrome (HOPE Study Group 2000; 
Daly et al 2005), and also include a post-hoc analysis of the 
SMILE Study performed in diabetic patients (Borghi et al 
2003). The relative risk reduction achieved in our study, 
even considering the differences in type of end points and 
treatment duration among the referred studies, and the fact 
that half our patients had hyperglycemia, exceeds that previ-
ously reported.
Our study also demonstrates that the prevalence of the 
MS in patients presenting at the hospital within 24 hours of 
an acute anterior myocardial infarction and not reperfused 
is high, in agreement with only two available publications on 
this topic (Ninomiya et al 2004; Zeller et al 2005).
Interestingly, the reduction in morbidity and mortality 
observed in the SMILE post-hoc study was largely indepen-
dent of blood pressure reduction, suggesting that zofenopril 
may affect MS+ patient’s prognosis beyond and in addition 
to its hemodynamic effect. This may be plausible, since 
both myocardial infarction and MS are associated with a 
neurohumoral activation which involves the sympathetic 
nervous system and the renin-angiotensin system (Walsh 
et al 1999). In particular in MS+ patients this activation might 
be also related to the condition of insulin resistance and to 
the consequent hyperinsulinemia that has been frequently 
described (Eckel et al 2005), and that could be responsible 
for a concentration-dependent overexpression of AT1 recep-
tors for angiotensin II at the tissue level (Muller et al 2000). 
In particular in MS+ patients with myocardial infarction, this 
mechanism could negatively interact with the concomitant 
activation of circulating renin-angiotensin-system, thereby 
providing a reasonable explanation for the greater preven-
tive effects of ACE inhibition observed in the SMILE Study 
(Prasad and Quyyumi 2004). In addition, the beneﬁ  cial effects 
of ACE inhibition in post-myocardial infarction patients with 
MS can be also due to some primary protective effects of 
zofenopril against the deterioration of left ventricular func-
tion and the progression of the atherosclerotic disease that 
follows myocardial ischemia (Frascarelli et al 2004).
Some limitations of our study also deserve to be dis-
cussed. First, the study is based on a post-hoc analysis of 
the SMILE Study and might be underpowered to demon-
strate the study goal. However, a) it was based on 91% of 
the original study population, b) the randomization groups 
were well balanced, and c) the extent of relative risk reduc-
tion observed with zofenopril was similar or even greater 
than that observed in high risk patients with coronary disease 
treated with ACE inhibitors (Gustafsson et al 1999; Zuanetti 
et al 1997; Moye et al 1994; HOPE Study Group 2000; Daly 
Figure 2 One-year mortality (left panel) and cumulative incidence of death (right panel) in patients with (MS+) and without metabolic syndrome (MS–) treated with placebo 
or zofenopril.
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et al 2005). Second, this post-hoc analysis was retrospective. 
However, since no prospective studies on the acute beneﬁ  t 
of ACE inhibition in MS+ patients with non-thrombolyzed 
acute myocardial infarction are available, we must rely on 
evidence provided by the retrospective data which are the 
only data available for analysis. Third, for the deﬁ  nition of 
MS we rely on a modiﬁ  ed NCEP ATP III classiﬁ  cation, ie, 
we used body mass index as a surrogate of waist circumfer-
ence for deﬁ  ning abdominal obesity. Recent data suggest 
that the use of body mass index for the deﬁ  nition of MS do 
not negatively affect the assessment of the prevalence and 
prognostic impact of this condition in the general population 
(Hunt et al 2004). Moreover, we have a posteriori veriﬁ  ed 
that this co-linearity exists in a subgroup of the cohort that 
is still continuously followed up.
In conclusion, results of this post-hoc analysis of the 
SMILE Study demonstrate the striking beneﬁ  t of early admin-
istration of zofenopril in MS+ patients with acute anterior 
myocardial infarction and suggest the use of ACE inhibitors 
for the routine treatment of such patients.
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